UBS Group’s Vigil Neuroscience VIGL Stock Holding History

UBS Group’s Portfolio VIGL Stock Details VIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-302,468	Closed	-$2.4M	–	10973
2025 Q2	$2.4M	Buy	302,468 +302,302	+182,110%	+$1.36M	﹤0.01%	4625
2025 Q1	$295	Buy	166 +165	+16,500%	+$370	﹤0.01%	9845
2024 Q4	$2	Sell	1 -282	-100%	-$833	﹤0.01%	9856
2024 Q3	$962	Sell	283 -4,525	-94%	-$16.8K	﹤0.01%	8763
2024 Q2	$19.2K	Sell	4,808 -11,343	-70%	-$38.8K	﹤0.01%	7330
2024 Q1	$55.1K	Buy	+16,151	New	+$50.4K	﹤0.01%	6469
2023 Q2	–	Sell	-592	Closed	-$5.8K	–	9702
2023 Q1	$5.8K	Buy	592 +82	+16%	+$922	﹤0.01%	7986
2022 Q4	$6.38K	Buy	+510	New	+$6.26K	﹤0.01%	9040
2022 Q3	–	Sell	-2,448	Closed	-$6K	–	10972
2022 Q2	$6K	Buy	2,448 +1,528	+166%	+$6.04K	﹤0.01%	8730
2022 Q1	$6K	Buy	+920	New	+$12.1K	﹤0.01%	9002

Other funds holding VIGL

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group's VIGL Position: Q3 2025 in Review

UBS Group sold out of Vigil Neuroscience (VIGL) in Q3 2025, closing a stake of 302,468 shares — an estimated $2.4M sold.

UBS Group first reported a position in VIGL in Q1 2022 and held it in 10 quarters. The position peaked at $2.4M in Q2 2025. 2 funds tracked by Wall St. Rank hold VIGL as of Q3 2025.

UBS Group reported no remaining Vigil Neuroscience position as of Q3 2025 after selling out during the quarter.
UBS Group sold 302,468 Vigil Neuroscience shares in Q3 2025, an estimated $2.4M.
UBS Group first reported a position in Vigil Neuroscience in Q1 2022 and held it in 10 quarters.
UBS Group's Vigil Neuroscience position peaked at $2.4M in Q2 2025.
2 funds tracked by Wall St. Rank held Vigil Neuroscience as of Q3 2025.

Based on UBS Group's 13F filing for Q3 2025, filed 13 Nov 2025.